Compumedics Limited · ASX:CMP
Compumedics — FY2003 Earnings Presentation
15 slides from Compumedics's earnings presentation, September 2003
Slide 1: Full year results
Full year results Compumedics Limifed 12 months ended -. 30 June, 2003
Slide 2: Outline
Outline 1. Results at 30 June 2003 2. Strategy focussed and effective 3. Future development.
Slide 3: Full year results - Key points
Slide 4: Key initiatives completed during the year
Key initiatives completed during the year @ 3 year $10m European distribution agreement with Drager Medical in place @ FDA clearance for Somté into the USA @ Melbourne factory relocated to new world class facility @ USA business relocated @ Patents for novel diagnostic sleep. treatment awarded @ Com
Slide 5: Historical Sales Graph
Historical Sales Graph A$m 30; 251 20 15) 10; 5; Export Sales "95 "96 197 "98 99. 00-01 02 Other Income 03
Slide 6: Strong growth in USA and Europe
Strong growth in USA and Europe 2002 Asia Europe 25% 2003 Lg Europe Asia 17% USA 17% 21% 47% _—— Australia 11% USA 51%
Slide 7: Sales by business segment 2002 vs 2003
A$m 357 307 257 207 157 2002 2003 @ NeuroMedical Supplies © Sleep @Neuroscan H Neuroscience
Slide 8: Global market breakdown for 2003
2900 1997. 1998 «=«1999 2000» 2001S 2002S 20032004. 2005. 2008 ~=-2007 Global market breakdown for 2003: + Sleep diagnostics : : USD140m *-Neurological diagnostics SA USD440m + Brain Research >. SSNS USD15m + Sleep Treatment “USD780m + Cardiology diagnostics oS USD290m Total Market ene “USD1,365m
Slide 9: Operating results
Operating Revenue 19.8 32.1 0.9 33.0 EBITDA (0.9) 2.1 0.9 3.0 EBIT (2.4) (18.8) 18.8 0.0 Profit after Tax (1.9) (18.6) 18.7 0.1 Gross Margin 64% 57% 59% EBITDA/Op. (5)% 6% 9% Revenue
Slide 10: Balance Sheet relative to PCP
Balance Sheet relative to PCP June 2003 A$'000 Current Assets Cash 5,366 Receivables 8,624 inventory : 8,416 Other __180 Total 22,586 Non current assets Receivables - Property, Plant and Equipment 1,176 Intangibles - Other = Total assets 23,762 Current liabilities Accounts payable 4,578 Borrowings 4
Slide 11: Financial Performance
Financial Performance @ Underlying operating earnings — Growth and efficiencies have significantly contributed to earnings. This has resulted in a positive shift in EBITDA to $2.1m @ Costs under focus — Critical mass in place, earnings continue to grow — . Efficiencies in all parts of the business t
Slide 12: La Le.
La Le. aaa
Slide 13: ee
ee 13
Slide 14: sath hha
LB, sath hha
Slide 15: Conclusions
Conclusions 1. Strong revenue growth up 62% year on year. 2. Profits restored at the EBITDA line. 3. Intangible asset reviews are behind us. 4. Expanding product offering in growing markets will fuel growth. 5. Profitable growth is the focus. 15